First Pass

24 stories from 11 sources

Outbreaks surge as healthcare systems face pressure and setbacks

Day’s Recap

Supporting Articles

12:52 PMAl Jazeera

DR Congo Ebola epidemic becomes world’s second largest outbreak

Summary

Officials said the Ebola epidemic in the Democratic Republic of Congo had become the world's second-largest outbreak and was spreading at an unprecedented pace. They urged greater international attention to contain it.

The outbreak's rapid expansion indicates that local response capacity is being outpaced by transmission, logistics,

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A rapidly expanding Ebola outbreak raises the risk of wider regional transmission and exposes the consequences of delayed global mobilization.

Link to Story

2 stories · 2 sources

8:28 AMStat News

Federal government could improve infectious disease monitoring, says federal government

Summary

The health update reports that the nominee to lead the CDC is advancing to a full Senate vote, while Medicaid work requirements will proceed without delay. It also points to potential federal improvements in infectious disease monitoring.

The immediate policy shift is that both CDC leadership and Medicaid implementation are moving forward

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Federal decisions on CDC leadership, Medicaid access, and disease surveillance could simultaneously affect outbreak preparedness and healthcare coverage.

Link to Story
7:00 AMCNBC

New Medicaid work rules could cause patients to lose coverage, rare disease advocates warn

Summary

Rare disease advocates warn that new Medicaid work requirements could cause patients and caregivers to lose coverage, even when illness limits their ability to work or complete administrative tasks. They are advising affected families to prepare for the changes.

The main risk is procedural as much as medical: eligible patients could lose coverage because

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Coverage interruptions can quickly disrupt specialist care, medicines and services that rare disease patients cannot easily replace.

Link to Story
5:00 AMNPR Politics

Ahead of midterms, Republicans run ads after cutting healthcare funds

Summary

Republican candidates who supported the One Big Beautiful Bill Act are airing ads that portray them as advocates for lower healthcare costs. The campaign comes after the law reduced federal healthcare funding.

Republicans are trying to reframe a record of reducing federal healthcare support as a promise

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Healthcare gives Democrats a direct way to tie Republican votes on the bill to household costs in competitive races.

Link to Story
2:56 PMThe City

Upper East Side Legionnaires’ Outbreak is Quelled, Health Commissioner Says

Summary

New York City health officials declared the Upper East Side Legionnaires’ disease outbreak over after the two-week incubation period for linked cases passed. The outbreak killed seven people, and officials said no further cases tied to the cluster had emerged.

The immediate public-health threat has ended, but the death toll leaves questions about how the

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The outbreak is contained, but its causes and the adequacy of local building-safety oversight remain consequential.

Link to Story

3 stories · 3 sources

9:54 AMMarketWatch

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Summary

Novo Nordisk shares fell sharply after the Danish healthcare company reported that a Phase 3 trial had failed.

The failed study adds another setback to Novo Nordisk's effort to sustain growth beyond its

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The result puts pressure on Novo Nordisk's future growth strategy, not just its share price.

Link to Story

2 stories · 2 sources

8:32 AMStat News

STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study

Summary

A Novo Nordisk drug failed to meet its goal in a heart disease study, raising doubts about whether targeting inflammation can prevent cardiovascular complications.

The result weakens the case for this specific anti-inflammatory approach in cardiovascular prevention and adds

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The failed study challenges a promising strategy for preventing cardiovascular disease and narrows Novo Nordisk's pipeline options.

Link to Story
3:21 AMBloomberg Markets

European Stocks Trim Monthly Gain as Novo Nordisk and UMG Slump

Summary

European shares gave back Friday's gains after Novo Nordisk fell on a failed drug study and Universal Music Group dropped to a record low following disappointing earnings.

Novo Nordisk's setback weakened both the company and the broader healthcare sector, helping erase part

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A clinical failure at one of Europe's biggest drugmakers is now affecting both sector sentiment and broader equity markets.

Link to Story
8:55 AMAl Jazeera

The waiting game: Gaza’s CT scan shortage causing worries and worse

Summary

A shortage of CT scanners in Gaza is delaying diagnostic examinations and worsening the medical crisis. Patients face longer waits for information needed to identify injuries and guide treatment.

The decisive constraint is the lack of functioning CT capacity, which turns diagnosis into a

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The shortage is converting limited medical infrastructure into delayed diagnoses, preventable deterioration, and harder treatment decisions.

Link to Story
1:02 PMStat News

STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitals

Summary

The Trump administration revised its planned rebate pilot for the 340B drug discount program, prompting opposition from hospitals. The changes move the pilot toward implementation while preserving a model that providers say could impose significant administrative burdens.

The revision does not settle the core conflict over who should manage and receive 340B

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The pilot could alter the financial mechanics of a major drug-discount program used by hospitals serving vulnerable patients.

Link to Story

Other Developments

A curated list of other prominent stories from this day.

11:18 PMAl Jazeera

Liberia’s kush crisis: The hidden trade behind a generation at risk

Summary

Kush, a dangerous synthetic drug, is spreading across Liberia and leaving families to manage its social and health consequences. The people driving the trade remain largely beyond the reach of authorities.

The crisis is shifting the burden from traffickers to households and an already strained public

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Liberia’s kush epidemic shows how an illicit drug market can become a long-term public health crisis when enforcement and treatment fail to keep pace.

Link to Story
6:10 PMAl Jazeera

US Senate’s Fauci hearing renews COVID origin debate but reveals little

Summary

A Senate hearing featuring Anthony Fauci revived the dispute over COVID-19's origins but produced little new evidence. The session reflected the partisan divide surrounding the issue and the influence of misleading claims from the White House.

The hearing changed the political temperature more than the factual record. Without new evidence, the

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The unresolved debate will continue to shape public trust in health agencies and future pandemic policy.

Link to Story
4:43 PMFinancial Times

KKR nears $4bn deal to buy medical device maker Integer Holdings

Summary

KKR is nearing an agreement worth more than $4 billion to acquire medical device maker Integer Holdings, which has also attracted attention from an activist hedge fund founded by an Elliott Management alumnus.

The potential deal would take Integer private and place its growth and operating strategy under

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The transaction signals continued private-equity appetite for medical device companies with opportunities to improve margins or consolidate operations.

Link to Story
12:56 PMMarketWatch

It’s getting easier for terminally ill people to end their own lives. What to know as laws change.

Summary

Medical-aid-in-dying laws are expanding, giving more terminally ill people a legal path to end their lives under defined safeguards. Eligibility generally depends on meeting three conditions, including a qualifying terminal illness and the ability to make and carry out the decision.

As more jurisdictions change their laws, access will depend increasingly on where patients live and

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The policy shift is widening end-of-life options while creating uneven access and new legal and clinical obligations.

Link to Story
10:47 AMStat News

STAT+: Up and down the ladder: The latest comings and goings

Summary

The roundup covers recent hires, departures, promotions and transfers across the pharmaceutical industry.

The personnel moves provide a snapshot of where drugmakers are adding or changing leadership and

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Leadership changes can reveal which therapeutic areas and business functions pharmaceutical companies consider most important.

Link to Story
9:28 AMStat News

STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more

Summary

An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma, despite the agency having rejected it twice before.

The panel's support creates a new regulatory opening for Replimune after two FDA rejections, but

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A favorable advisory vote could revive a melanoma drug's prospects while testing how much influence the panel has over FDA decisions.

Link to Story
4:30 AMStat News

Opinion: We once praised the American Diabetes Association’s courage. How things have changed

Summary

The authors argue that the American Diabetes Association has moved away from the independence and courage it once displayed. They present the organization’s current conduct as a departure from that earlier standard.

The central shift is the authors’ judgment that the ADA no longer acts as a

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A less independent diabetes advocacy group could weaken scrutiny of decisions affecting millions of patients.

Link to Story
4:30 AMStat News

Opinion: Limb girdle muscular dystrophy patients face a maddening reality

Summary

The author says regulatory pathways designed to speed access to breakthrough treatments are sometimes being applied in ways that block approval instead. Patients with limb girdle muscular dystrophy are left navigating a system that promises faster access but can produce delay.

The decisive problem is a gap between the purpose of accelerated regulatory tools and their

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Regulatory failure in rare diseases can turn promising therapies into years of additional waiting for patients with limited time.

Link to Story
4:30 AMStat News

Syphilis spreads while researchers contend with federal constraints and a drug shortage

Summary

Syphilis is spreading in the San Diego-Tijuana border region as researchers face federal restrictions and a shortage of treatment. The overlapping public health and research obstacles complicate efforts to contain transmission.

The outbreak is colliding with two preventable constraints: limited access to a key drug and

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A treatable infection becomes harder to control when medicine shortages and research barriers hit the same vulnerable region.

Link to Story
4:30 AMStat News

Opinion: What a recent op-ed got wrong about our Covid study

Summary

The authors respond to an op-ed they say misrepresented their Covid study. They argue that assessing the U.S. pandemic response requires careful, rigorous, and honest interpretation of the evidence rather than revisionist claims.

The immediate conflict is over how research findings should be used in the broader debate

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Disputes over Covid evidence still shape public trust in science and future pandemic policy.

Link to Story

Make it yours

Build Your First Pass.

Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!